Candel Therapeutics (CADL) Invested Capital (2020 - 2025)

Candel Therapeutics has disclosed Invested Capital across 6 years of filings, most recently posting $51.9 million for Q4 2025.

• Invested Capital for Q4 2025 came in at $51.9 million, down 31.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $51.9 million (down 31.88% YoY), and the FY2025 annual result was $51.9 million, down 31.88% from the prior year.
• Invested Capital came in at $51.9 million for Q4 2025 at Candel Therapeutics, down from $84.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $96.9 million in Q2 2025 to a low of -$42.7 million in Q2 2021.
• The 5-year median for Invested Capital is $57.7 million (2021), against an average of $44.6 million.
• Across the five-year window, Invested Capital slumped 245.63% in 2021 and jumped 59556.44% in 2025, its largest moves.
• Candel Therapeutics' Invested Capital stood at $64.7 million in 2021, then advanced by 4.66% to $67.7 million in 2022, then sank by 68.05% to $21.6 million in 2023, then jumped by 252.26% to $76.2 million in 2024, then plunged by 31.88% to $51.9 million in 2025.
• The last three Invested Capital figures came in at $51.9 million (Q4 2025), $84.3 million (Q3 2025), and $96.9 million (Q2 2025), per Business Quant data.